Repligen
RGEN
#2575
Rank
โ‚ฌ5.75 B
Marketcap
102,23ย โ‚ฌ
Share price
-0.46%
Change (1 day)
-3.28%
Change (1 year)
Categories

Repligen (RGEN) - Total liabilities

Total liabilities on the balance sheet as of December 2025 : โ‚ฌ0.73 Billion

According to Repligen 's latest financial reports the company's total liabilities are โ‚ฌ0.73 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Repligen - Total liabilities on balance sheet (from 2001 to 2025)

Total liabilities by year

Year Total liabilities Change
2025-12-31โ‚ฌ0.71 B-12.8%
2024-12-31โ‚ฌ0.82 B5.08%
2023-12-31โ‚ฌ0.78 B35.39%
2022-12-31โ‚ฌ0.57 B7.77%
2021-12-31โ‚ฌ0.53 B76.77%
2020-12-31โ‚ฌ0.30 B0.01%
2019-12-31โ‚ฌ0.30 B118.52%
2018-12-31โ‚ฌ0.13 B9.77%
2017-12-31โ‚ฌ0.12 B10.88%
2016-12-31โ‚ฌ0.11 B431.72%
2015-12-31โ‚ฌ21.48 M57.76%
2014-12-31โ‚ฌ13.61 M27.42%
2013-12-31โ‚ฌ10.68 M9.71%
2012-12-31โ‚ฌ9.74 M
2011-03-31โ‚ฌ3.67 M-5.73%
2010-03-31โ‚ฌ3.9 M11.54%
2009-03-31โ‚ฌ3.49 M16.75%
2008-03-31โ‚ฌ2.99 M12.97%
2007-03-31โ‚ฌ2.65 M0.35%
2006-03-31โ‚ฌ2.64 M2.83%
2005-03-31โ‚ฌ2.56 M29.66%
2004-03-31โ‚ฌ1.98 M-4.35%
2003-03-31โ‚ฌ2.07 M-32.19%
2002-03-31โ‚ฌ3.05 M112.96%
2001-03-31โ‚ฌ1.43 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Pfizer
PFE
โ‚ฌ105.36 B 14,289.44%๐Ÿ‡บ๐Ÿ‡ธ USA
Thermo Fisher Scientific
TMO
โ‚ฌ49.30 B 6,634.12%๐Ÿ‡บ๐Ÿ‡ธ USA
General Electric
GE
โ‚ฌ96.58 B 13,090.49%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚ฌ62.08 B 8,379.68%๐Ÿ‡บ๐Ÿ‡ธ USA
Sangamo Therapeutics
SGMO
โ‚ฌ71.52 M-90.23%๐Ÿ‡บ๐Ÿ‡ธ USA
Novavax
NVAX
โ‚ฌ1.13 B 54.61%๐Ÿ‡บ๐Ÿ‡ธ USA
Neurocrine Biosciences
NBIX
โ‚ฌ1.19 B 63.40%๐Ÿ‡บ๐Ÿ‡ธ USA
Bio-Techne
TECH
โ‚ฌ0.44 B-39.34%๐Ÿ‡บ๐Ÿ‡ธ USA
BioMarin Pharmaceutical
BMRN
โ‚ฌ1.30 B 78.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Charles River Laboratories
CRL
โ‚ฌ3.40 B 365.19%๐Ÿ‡บ๐Ÿ‡ธ USA